Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system.

Kirou KA, Salmon JE, Crow MK.

Rheum Dis Clin North Am. 2006 Feb;32(1):103-19, ix. Review.

PMID:
16504824
2.

Newer therapeutic approaches for systemic lupus erythematosus: immunosuppressive agents.

Dooley MA, Ginzler EM.

Rheum Dis Clin North Am. 2006 Feb;32(1):91-102, ix. Review.

PMID:
16504823
3.

Anticytokine therapy in systemic lupus erythematosus.

Yoo DH.

Lupus. 2010 Oct;19(12):1460-7. doi: 10.1177/0961203310376955. Review.

PMID:
20947558
4.

Mechanisms of Disease: the complement system and the pathogenesis of systemic lupus erythematosus.

Cook HT, Botto M.

Nat Clin Pract Rheumatol. 2006 Jun;2(6):330-7. Review.

PMID:
16932712
5.

Systemic lupus erythematosus--2005 annus mirabilis?

Isenberg D, Rahman A.

Nat Clin Pract Rheumatol. 2006 Mar;2(3):145-52. Review.

PMID:
16932674
6.

Systemic lupus erythematosus in children: current and emerging therapies.

Macdermott EJ, Adams A, Lehman TJ.

Lupus. 2007;16(8):677-83. Review.

PMID:
17711907
7.

Systemic lupus erythematosus: modern strategies for management: a moving target.

King JK, Hahn BH.

Best Pract Res Clin Rheumatol. 2007 Dec;21(6):971-87. Review.

PMID:
18068856
8.

Treating lupus: from serendipity to sense, the rise of the new biologicals and other emerging therapies.

Sousa E, Isenberg D.

Best Pract Res Clin Rheumatol. 2009 Aug;23(4):563-74. doi: 10.1016/j.berh.2008.12.006.

PMID:
19591785
9.

Newer therapeutic approaches for systemic lupus erythematosus.

Ginzler EM, Dvorkina O.

Rheum Dis Clin North Am. 2005 May;31(2):315-28. Review.

PMID:
15922148
10.

Update on complement in the pathogenesis of systemic lupus erythematosus.

Molina H.

Curr Opin Rheumatol. 2002 Sep;14(5):492-7. Review.

PMID:
12192243
11.

Antibody-based therapies in systemic lupus erythematosus.

Iikuni N, La Cava A.

Mini Rev Med Chem. 2009 Jun;9(7):829-46. Review.

PMID:
19519508
12.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
13.

Novel molecular targets for systemic lupus erythematosus.

Marino M, Rossi M, Ruvo M, Fassina G.

Curr Drug Targets. 2002 Jun;3(3):223-8. Review.

PMID:
12041736
15.

B cells in SLE: different biological drugs for different pathogenic mechanisms.

Diamanti AP, Rosado MM, Carsetti R, Valesini G.

Autoimmun Rev. 2007 Dec;7(2):143-8. Epub 2007 Mar 22. Review.

PMID:
18035325
16.

Ocular manifestations of systemic lupus erythematosus.

Davies JB, Rao PK.

Curr Opin Ophthalmol. 2008 Nov;19(6):512-8. Review.

PMID:
18998618
17.

Complement and systemic lupus erythematosus.

Karp DR.

Curr Opin Rheumatol. 2005 Sep;17(5):538-42. Review.

PMID:
16093830
18.

Possible therapeutic applications of single-chain antibodies in systemic autoimmune diseases.

Angyal A, Prechl J, Sármay G.

Expert Opin Biol Ther. 2007 May;7(5):691-704. Review.

PMID:
17477806
19.

[Immunomodulation therapy for autoimmune diseases. New hope for patients with autoimmune diseases].

Szegedi G.

Orv Hetil. 2005 Apr 3;146(14):635-43. Review. Hungarian.

PMID:
15889537
20.

Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside.

Zandman-Goddard G, Blank M, Shoenfeld Y.

Lupus. 2009 Sep;18(10):884-8. doi: 10.1177/0961203309106921. Review.

PMID:
19671787

Supplemental Content

Support Center